89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
Portfolio Pulse from
89bio, Inc. is advancing its drug pegozafermin for the treatment of Severe Hypertriglyceridemia (SHTG), with phase 3 results expected in the second half of 2025. Previous phase 2 results were promising, achieving the primary endpoint with statistical significance. The SHTG treatment market is projected to grow significantly by 2033.
January 13, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
89bio, Inc. is advancing pegozafermin for SHTG, with promising phase 2 results and phase 3 results expected in 2025. The SHTG market is projected to grow, indicating potential revenue opportunities.
The advancement of pegozafermin into phase 3 trials, with promising phase 2 results, suggests potential success in treating SHTG. The projected growth of the SHTG market to $2.67 billion by 2033 indicates significant revenue opportunities for 89bio, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100